Plant-Derived Extracellular Vesicles and Their Exciting Potential as the Future of Next-Generation Drug Delivery.
Faisal Abdulrahman AlzahraniMohammad Imran KhanNader KameliElham AlsahafiYasir Mohamed RizaPublished in: Biomolecules (2023)
Plant cells release tiny membranous vesicles called extracellular vesicles (EVs), which are rich in lipids, proteins, nucleic acids, and pharmacologically active compounds. These plant-derived EVs (PDEVs) are safe and easily extractable and have been shown to have therapeutic effects against inflammation, cancer, bacteria, and aging. They have shown promise in preventing or treating colitis, cancer, alcoholic liver disease, and even COVID-19. PDEVs can also be used as natural carriers for small-molecule drugs and nucleic acids through various administration routes such as oral, transdermal, or injection. The unique advantages of PDEVs make them highly competitive in clinical applications and preventive healthcare products in the future. This review covers the latest methods for isolating and characterizing PDEVs, their applications in disease prevention and treatment, and their potential as a new drug carrier, with special attention to their commercial viability and toxicological profile, as the future of nanomedicine therapeutics. This review champions the formation of a new task force specializing in PDEVs to address a global need for rigor and standardization in PDEV research.
Keyphrases
- small molecule
- papillary thyroid
- drug delivery
- healthcare
- current status
- squamous cell
- coronavirus disease
- sars cov
- induced apoptosis
- oxidative stress
- cancer therapy
- cell wall
- risk assessment
- drug induced
- emergency department
- machine learning
- liver injury
- cell cycle arrest
- squamous cell carcinoma
- cell proliferation
- endoplasmic reticulum stress
- combination therapy
- ultrasound guided
- artificial intelligence
- ulcerative colitis
- climate change
- adverse drug